Crossmark

Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination

Crossref DOI link: https://doi.org/10.1186/s13075-022-02762-5

Published Online: 2022-03-21

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vittecoq, Olivier

Guillou, Clément

Hardouin, Julie

Gerard, Baptiste

Berenbaum, Francis

Constantin, Arnaud

Rincheval, Nathalie

Combe, Bernard

Lequerre, Thierry

Cosette, Pascal
License Information

Text and Data Mining valid from 2022-03-21

Version of Record valid from 2022-03-21
More Information

Article History

Received: 24 January 2022

Accepted: 24 February 2022

First Online: 21 March 2022

Declarations

:

: The ESPOIR study was conducted with the approval of the Institutional Review Board of Montpellier University Hospital. All patients gave their signed informed consent to participate in the cohort (ClinicalTrials.gov identifier: NCT03666091). Concerning patients included in the SATRAPE study (ClinicalTrials.gov.identifier: NCT00234234), the study was approved by the regional ethics committee (CPP Nord Ouest 1, France) and all participants gave written informed consent at the time of enrolment.

: No individual person’s data are present in the manuscript. All data are completely anonymized.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below